David Teachey Laboratory
Clinical trials are underway at the Center for Childhood Cancer Research to evaluate the use of sirolimus as a treatment for refractory pediatric autoimmune diseases.
Researchers at the Center for Childhood Cancer Research are creating computer-based methods to collect, analyze and share clinical data to improve pediatric cancer care and treatment.
Clinical studies conducted by physician scientists at the CCCR have demonstrated that administration of tocilizumab — a recombinant humanized anti-IL6 receptor monoclonal antibody that interferes with secretion of the cytokine IL6 — can be an effective treatment for pediatric patients who develop cytokine release syndrome (CRS) after CART or BiTE therapy.
Early stage clinical trials in partnership with the Children’s Oncology Group (COG) are being developed to evaluate the efficacy and safety of a combination of ruxolitinib with standard chemotherapy to treat high-risk ALL with dysregulated Jak /STAT signaling mutations.